SAN CARLOS, Calif., Nov. 1, 2017 /PRNewswire/ -- Alkahest, Inc. ("Alkahest"), a clinical-stage biotechnology company focusedon developing innovative therapies to treat age-related diseases, today announced an upcoming oral presentation at the 10th Clinical Trials on Alzheimer's Disease (CTAD) conference. The Principal Investigator, Sharon
"We are pleased to present these results from the PLASMA study, which demonstrate the safety of plasma-derived products and suggest their potential efficacy in Alzheimer's disease," said Karoly Nikolich, Ph.D., Chief Executive Officer of Alkahest. "These data add to the growing body of evidence supporting the ability of plasma compositions to counteract the biological processes underlying neurodegeneration, and reaffirm our confidence in our pipeline of first-in-class products targeting the pathways implicated in age-related disease. We look forward to advancing our lead clinical candidate, a proprietary plasma fraction, as a potential treatment for mild to moderate Alzheimer's disease."
The PLasma for Alzheimer SymptoM Amelioration (PLASMA) Study Presenter: Sharon Sha, MD, MS, Clinical Associate Professor, Neurology & Neurological Sciences, Stanford UniversityDate: Saturday, November 4th, 2017Time: 3:45 pm Eastern TimeLocation: Boston Park Plaza Hotel
The primary objective of the PLASMA study was to evaluate the safety, tolerability and feasibility of repeated infusions of plasma from 18-30 year-old donors in patients with mild to moderate AD. Secondary objectives included evaluating the effect of plasma infusions on multiple clinical assessments, including assessments of functional activity. Nine subjects were enrolled, randomized and treated under the double-blind crossover protocol, and an additional nine subjects were enrolled and treated under an open-label amendment. Results indicate that the plasma infusions were generally well-tolerated, with no treatment-related serious adverse events. The results also demonstrated statistically-significant improvement in clinical assessments of functional activity.
Based on the robust safety profile and signals of efficacy seen in the PLASMA study, Alkahest plans to advance the clinical development of a proprietary next-generation plasma-derived product for the treatment of mild-moderate AD.
About AlkahestAlkahest is a privately-held company based in San Carlos, CA developing treatments for age-related diseases, with an emphasis on cognitive dysfunction and neurodegeneration key medical challenges of our generation. The Company's breakthrough research has demonstrated that healthy blood plasma is able to reverse brain deficits in normal aging and disease models in animals. Alkahest is developing a pipeline of first-in-class products, including novel plasma-based products in collaboration with Grifols, a global healthcare company and leading producer of plasma therapies. Alkahest's lead clinical candidate is a proprietary plasma-derived product that has been demonstrated to enhance cognition in preclinical studies and is well-tolerated in humans. It is currently in clinical development for the treatment of Alzheimer's disease and will be produced by Grifols. For further information, see www.alkahest.com.
Contact Information:Joe McCrackenVice President Business DevelopmentAlkahest, Inc.email@example.com
Matthew ShinsekiStern Investor Relations, Inc.212-362-1200 firstname.lastname@example.org
View original content:http://www.prnewswire.com/news-releases/alkahest-to-present-clinical-results-from-plasma-study-in-patients-with-mild-to-moderate-alzheimers-disease-at-the-10th-clinical-trials-on-alzheimers-disease-ctad-conference-300545562.html
SOURCE Alkahest, Inc.
Subscribe to our Free Newsletters!
Exfoliative dermatitis or erythroderma is a skin condition where the skin becomes reddened and ...
Alström syndrome, a rare genetic disorder due to ALMS1 mutations, occurs in the first year of ...
Sodium zirconium cyclosilicate was approved by FDA recently to use as an oral suspension for ...View All